Resonance Health Ltd · ASX:RHT
Resonance Health — Shareholder Meeting (November 2008)
13 slides from Resonance Health's shareholder meeting presentation, Nov 26, 2008
Slide 1: Resonance Health Limited Annual General Meeting
For personal use only Resonance Health Limited ACN 006 762 492 Annual General Meeting 26 November 2008
Slide 2: Summary
Summary For personal use only Our Business: Resonance Health provides core laboratory and MRI analysis services using advanced, patented technology to assist with the diagnosis and management of disease Lead Product: FerriScan® – accurate assessment of liver iron Revenue lines: FerriScan image analy
Slide 3: Year in Review
Year in Review For personal use only Aug 07 Terminated US Pathology acquisition strategy, reduce board size, terminated employment of US CEO Sept 07 Renegotiated long term contract with customers (contract values >$4m 2008-2011) Sept 07 Commenced FerriScan services to MDS (myelodysplasia) market Oct
Slide 4: FerriScan Market
FerriScan Market For personal use only • Transfusional Iron overload: – Thalassaemia – Sickle Cell Anaemia – Myelodysplasia • Primary Iron overload – Hemochromatosis – Excess iron absorption from the diet • A patients liver iron concentration value is the best measure of total body iron stores.
Slide 5: FerriScan Market
FerriScan Market For personal use only • Hereditary Haemochromatosis – Approx 1 in 20 in populations from Northern European descent • Thalassaemia Major – Over 100,000 new severe cases born every year in belt stretching from Middle East through to SE Asia – Affects over 1m people world wide • Sickle
Slide 6: FerriScan
FerriScan For personal use only • Non-invasive MRI based technique • Analysis of the image data is perfomed by Resonance Health at an ISO:9001 quality assured analysis centre • No special MRI hardware or software required • Provides clinicians with accurate information required for managing the trea
Slide 7: Example: FerriScan measurements to monitor iron chelation therapy
Example: FerriScan measurements to monitor iron chelation therapy For personal use only Before chelation therapy intervention Mean LIC = 16.0 After 12 months of chelation therapy intervention Mean LIC = 1.6 LIC map Low High iron iron
Slide 8: Market Acceptance
Market Acceptance For personal use only • FerriScan aims to replace liver biopsy as the new ‘gold standard’ for measuring liver iron concentration. • Recently published patient management guidelines recommend FerriScan for the management of patient with iron overload: – Thalassaemia International Fe
Slide 9: FerriScan Availability
FerriScan Availability For personal use only • FerriScan works on most MRI scanners available today • The FerriScan team provides clear instructions and on-line support to help radiologists implement the technique • FerriScan has been successfully implemented in over 20 countries.
Slide 10: Reimbursement
Reimbursement For personal use only • Australian submission for Medicare funding for FerriScan – Decision expected end 2009 • Some UK reimbursement for FerriScan – Program to extend this to other hospitals – UK representative • Ontario, Canada MOH reimbursement for FerriScan – Program to extend this
Slide 11: FibroScreen
FibroScreen™ For personal use only • Aim to develop an accurate test for measuring liver Fibrosis at early disease stage • Fibrosis Market: – Hepatitis – 5 million people worldwide – Fatty Liver Disease – 40 million people in the USA • Existing tests lack sensitivity at early stage fibrosis • 18 mon
Slide 12: Financial Results
Financial Results For personal use only AUD 2005-6 2006-7 2007-8 FerriScan # 912 1945 1605 FerriScan Revenue* $313,532 $1,868,790 $1,722,085 Expenses ($4,119,663)** ($3,071,961) ($2,137,015) Net (Loss) A/ Tax ($3,273,957)** ($725,319) ($41,392) Cash $0.6m $2.4m $2.4m * excludes grant and interest in
Slide 13: Strategy
Strategy For personal use only • Expand relationship with large Pharma • Gain reimbursement for FerriScan and follow with marketing push • Expand revenue base – Expand product offerings – cardiac iron, liver fibrosis – Expand core laboratory service capabilities • Manage risks – Clinical trial reven
Resonance Health — Shareholder Meeting (November 2008) on 6ix